Author:
Guselnikov Sergey V.,Baranov Konstantin O.,Kulemzin Sergey V.,Belovezhets Tatyana N.,Chikaev Anton N.,Murasheva Svetlana V.,Volkova Olga Y.,Mechetina Ludmila V.,Najakshin Alexander M.,Chikaev Nikolai A.,Solodkov Pavel P.,Sergeeva Maria V.,Smirnov Alexander V.,Serova Irina A.,Serov Oleg L.,Markhaev Alexander G.,Kononova Yulia V.,Alekseev Alexander Y.,Gulyaeva Marina A.,Danilenko Daria M.,Battulin Nariman R.,Shestopalov Alexander M.,Taranin Alexander V.
Abstract
The COVID-19 pandemic has uncovered the high genetic variability of the SARS-CoV-2 virus and its ability to evade the immune responses that were induced by earlier viral variants. Only a few monoclonal antibodies that have been reported to date are capable of neutralizing a broad spectrum of SARS-CoV-2 variants. Here, we report the isolation of a new broadly neutralizing human monoclonal antibody, iC1. The antibody was identified through sorting the SARS-CoV-1 RBD-stained individual B cells that were isolated from the blood of a vaccinated donor following a breakthrough infection. In vitro, iC1 potently neutralizes pseudoviruses expressing a wide range of SARS-CoV-2 Spike variants, including those of the XBB sublineage. In an hACE2-transgenic mouse model, iC1 provided effective protection against the Wuhan strain of the virus as well as the BA.5 and XBB.1.5 variants. Therefore, iC1 can be considered as a potential component of the broadly neutralizing antibody cocktails resisting the SARS-CoV-2 mutation escape.
Funder
Ministry of Science and Higher Education of the Russian Federation